Harvard Bioscience (NASDAQ:HBIO) Issues Earnings Results

Harvard Bioscience (NASDAQ:HBIO) issued its quarterly earnings data on Tuesday. The medical instruments supplier reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.29, FiscalAI reports. Harvard Bioscience had a negative return on equity of 19.54% and a negative net margin of 65.51%.The company had revenue of $20.76 million during the quarter, compared to analysts’ expectations of $21.20 million.

Here are the key takeaways from Harvard Bioscience’s conference call:

• Harvard Bioscience said Q1 revenue of $20.8 million was in line with expectations, while adjusted gross margin improved to 59%, up about 300 basis points year over year.
• Management highlighted strong momentum in its new product innovation portfolio, especially Mesh MEA, BTX, and SoHo, and said these products are expected to drive double-digit revenue growth for the full year.
• Sales to pharma and large biotech customers grew more than 20% in the quarter, supporting the company’s push into translational science and more recurring, higher-margin revenue.
• Revenue was pressured by weaker academic and government demand in the Americas and lower distributor sales in APAC, though management said U.S. academic ordering should improve after NIH budget approvals and China returned to growth.
• The company reaffirmed full-year 2026 guidance, including 2%–4% revenue growth, 58%–60% gross margin, and 6%–10% adjusted EBITDA growth, and said Project Viking remains on track to deliver meaningful cost savings.

Harvard Bioscience Price Performance

HBIO stock traded up $0.13 on Wednesday, reaching $5.54. 27,118 shares of the company’s stock were exchanged, compared to its average volume of 51,327. The stock has a fifty day moving average of $5.65 and a 200-day moving average of $6.01. Harvard Bioscience has a twelve month low of $2.81 and a twelve month high of $9.50. The firm has a market cap of $24.99 million, a PE ratio of -0.43 and a beta of 1.57. The company has a quick ratio of 1.25, a current ratio of 2.20 and a debt-to-equity ratio of 2.61.

Insider Buying and Selling

In other Harvard Bioscience news, CEO John D. Duke acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were purchased at an average price of $5.01 per share, with a total value of $25,050.00. Following the completion of the acquisition, the chief executive officer directly owned 105,000 shares of the company’s stock, valued at approximately $526,050. The trade was a 5.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director William Snider acquired 12,525 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were acquired at an average cost of $4.99 per share, for a total transaction of $62,499.75. Following the acquisition, the director directly owned 23,525 shares of the company’s stock, valued at $117,389.75. This trade represents a 113.86% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 36,000 shares of company stock valued at $177,354 over the last quarter. Company insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP purchased a new position in shares of Harvard Bioscience in the second quarter valued at $61,000. Essex Investment Management Co. LLC purchased a new position in shares of Harvard Bioscience in the fourth quarter valued at $124,000. Two Sigma Investments LP increased its position in shares of Harvard Bioscience by 139.7% in the third quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock valued at $208,000 after buying an additional 276,372 shares in the last quarter. Corsair Capital Management L.P. increased its position in shares of Harvard Bioscience by 1,008.7% in the fourth quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock valued at $741,000 after buying an additional 1,008,692 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Harvard Bioscience by 17.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,021,241 shares of the medical instruments supplier’s stock valued at $683,000 after acquiring an additional 152,763 shares during the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. New Street Research set a $6.00 price target on Harvard Bioscience in a research note on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Friday, March 27th. Benchmark cut their price target on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a research note on Friday, March 13th. Finally, Wall Street Zen cut Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.00.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.